News
12-09-2009, 02:41 AM
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
More... (http://www.news-medical.net/news/20091209/Roche-to-present-data-on-its-Herceptin-Avastin-and-T-DM1-studies-at-the-CTRC-AACR-Symposium.aspx)
More... (http://www.news-medical.net/news/20091209/Roche-to-present-data-on-its-Herceptin-Avastin-and-T-DM1-studies-at-the-CTRC-AACR-Symposium.aspx)